Excellence in life sciences executive search

Entasis Retains The Chase Group for Senior Medical Director Infectious Diseases Role

July 7, 2017
Once again, Entasis Therapeutics has retained The Chase Group to build clinical/medical support for their CMO, Dr. Robin Isaacs. The Chase Group placed Dr. Robin Isaacs in his role and look forward to our continued partnership. Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Their deep pipeline of novel clinical and pre-clinical antibacterial programs is designed to revolutionize the way physicians treat serious bacterial diseases.

Chase Group

Share this Content

Copyright © 1993-2023 The Chase Group. All Rights Reserved.